1
|
Carrillo-Ávila JA, de la Fuente A, Aguilar-Quesada R, Ligero G, del Río-Ortiz JM, Catalina P. Development and Evaluation of a New qPCR Assay for the Detection of Mycoplasma in Cell Cultures. Curr Issues Mol Biol 2023; 45:6903-6915. [PMID: 37623254 PMCID: PMC10453501 DOI: 10.3390/cimb45080435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 08/11/2023] [Accepted: 08/16/2023] [Indexed: 08/26/2023] Open
Abstract
In recent years, cell culture has become an important tool not only in research laboratories, but also in diagnostic and biotechnological development laboratories. Mycoplasma contamination is present in up to 35% of cell cultures used in research and in cell therapies. This fact represents a significant problem since such contamination can cause disastrous effects on eukaryotic cells by altering their cellular parameters, which, in turn, can lead to unreliable experimental results. For this reason, it is mandatory to carry out continuous testing for the presence of Mycoplasma in cell culture and the development of appropriate methodologies for this purpose. An ideal detection methodology should be fast, sensitive, and reliable. In this study, we propose an alternative detection method based on real-time PCR in conjunction with a novel combination of primers and probes that have been improved to increase their efficiency. The new PCR method demonstrates 100% sensitivity and specificity results in the detection of common Mycoplasma species that contaminate cell cultures. Whilst 11 of 45 tested supernatants were positive for Mycoplasma (24.4%) using the new PCR method (corresponding to 5 of the 14 lines tested (35.71%)), only 10 of 45 supernatants showed positive results with the commercial Venor®GeM qEP and Plasmotest® kit. In addition, the new PCR method exhibits a high capacity to detect less-frequent Mycoplasma species, such as those related to the M. mycoides cluster. The use of an alternative Mycoplasma-detection method in cell culture labs can guarantee the detection of Mycoplasma contamination, especially in cases when dubious results are recorded.
Collapse
Affiliation(s)
- José A. Carrillo-Ávila
- Andalusian Public Health System Biobank, Coordinating Node, Av. del Conocimiento, S/N, 18016 Granada, Spain; (A.d.l.F.); (R.A.-Q.); (G.L.); (J.M.d.R.-O.); (P.C.)
| | | | | | | | | | | |
Collapse
|
2
|
Carrillo-Ávila JA, Aguilar-Quesada R, Ligero G, Panadero-Fajardo S, Santos-Pírez MV, Catalina P. Identification of cell culture contamination by an unusual species of Mycoplasma related to the M. mycoides cluster. Cytotechnology 2023; 75:135-141. [PMID: 36969572 PMCID: PMC10030751 DOI: 10.1007/s10616-022-00567-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Accepted: 12/27/2022] [Indexed: 01/06/2023] Open
Abstract
Mycoplasma contamination is a significant problem in cell culture replication and maintenance. From more than 200 known species, a limited number of Mycoplasma species have been detected in cell cultures, representing new species or variants that can escape detection systems. A qPCR commercial kit was used for Mycoplasma detection in cell cultures. Furthermore, an amplified Mycoplasma species was sequenced and summited for sequence assembly, clustering, and evolutionary analysis study. Our work has identified a new and unusual variant or species of Mycoplasma that possesses a high degree of homology with species related with M. mycoides cluster. This variant is usually associated with cattle but has been detected contaminating a cell culture. Mycoplasma testing (even for unusual species) in cell cultures is essential to ensure the validity and reproducibility of research that uses cell cultures and to ensure the quality of cell line deposits in biobanks. For this reason, it is necessary to perform continuous checks for the absence of Mycoplasma in cell cultures and engage in the continuous adaptation of relevant detection systems.
Collapse
Affiliation(s)
| | - R Aguilar-Quesada
- Andalusian Public Health System Biobank, Coordinating Node, Av. del Conocimiento, S/N, 18016 Granada, Spain
| | - G Ligero
- Andalusian Public Health System Biobank, Coordinating Node, Av. del Conocimiento, S/N, 18016 Granada, Spain
| | - S Panadero-Fajardo
- Andalusian Public Health System Biobank, Coordinating Node, Av. del Conocimiento, S/N, 18016 Granada, Spain
| | - M V Santos-Pírez
- Andalusian Public Health System Biobank, Coordinating Node, Av. del Conocimiento, S/N, 18016 Granada, Spain
| | - P Catalina
- Andalusian Public Health System Biobank, Coordinating Node, Av. del Conocimiento, S/N, 18016 Granada, Spain
| |
Collapse
|
3
|
Barone PW, Keumurian FJ, Neufeld C, Koenigsberg A, Kiss R, Leung J, Wiebe M, Ait-Belkacem R, Azimpour Tabrizi C, Barbirato C, Beurdeley P, Brussel A, Cassart JP, Cote C, Deneyer N, Dheenadhayalan V, Diaz L, Geiselhoeringer A, Gilleece MM, Goldmann J, Hickman D, Holden A, Keiner B, Kopp M, Kreil TR, Lambert C, Logvinoff C, Michaels B, Modrof J, Mullan B, Mullberg J, Murphy M, O'Donnell S, Peña J, Ruffing M, Ruppach H, Salehi N, Shaid S, Silva L, Snyder R, Spedito-Jovial M, Vandeputte O, Westrek B, Yang B, Yang P, Springs SL. Historical evaluation of the in vivo adventitious virus test and its potential for replacement with next generation sequencing (NGS). Biologicals 2023; 81:101661. [PMID: 36621353 DOI: 10.1016/j.biologicals.2022.11.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Accepted: 11/29/2022] [Indexed: 01/09/2023] Open
Abstract
The Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) collected historical data from 20 biopharmaceutical industry members on their experience with the in vivo adventitious virus test, the in vitro virus test, and the use of next generation sequencing (NGS) for viral safety. Over the past 20 years, only three positive in vivo adventitious virus test results were reported, and all were also detected in another concurrent assay. In more than three cases, data collected as a part of this study also found that the in vivo adventitious virus test had given a negative result for a sample that was later found to contain virus. Additionally, the in vivo adventitious virus test had experienced at least 21 false positives and had to be repeated an additional 21 times all while using more than 84,000 animals. These data support the consideration and need for alternative broad spectrum viral detection tests that are faster, more sensitive, more accurate, more specific, and more humane. NGS is one technology that may meet this need. Eighty one percent of survey respondents are either already actively using or exploring the use of NGS for viral safety. The risks and challenges of replacing in vivo adventitious virus testing with NGS are discussed. It is proposed to update the overall virus safety program for new biopharmaceutical products by replacing in vivo adventitious virus testing approaches with modern methodologies, such as NGS, that maintain or even improve the final safety of the product.
Collapse
Affiliation(s)
| | | | | | | | - Robert Kiss
- MIT Center for Biomedical Innovation, USA; UPSIDE Foods, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Zorzi AR, Antonioli E, Godoy JAPD, Okamoto OK, Kondo AT, Kutner JM, Kaleka CC, Cohen M, Ferretti M. Report of a clinical and laboratory management of cell therapy for knee cartilage in the face of mycoplasma contamination. EINSTEIN-SAO PAULO 2022; 20:eRC6918. [PMID: 35730808 PMCID: PMC9239536 DOI: 10.31744/einstein_journal/2022rc6918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Accepted: 09/29/2021] [Indexed: 11/25/2022] Open
Abstract
To describe a case of autologous chondrocyte implantation after cell culture contamination by Mycoplasma pneumoniae and the measures taken to successfully complete cell therapy in a patient with focal chondral lesion. A 45-year-old male patient, complaining of chronic pain on the knee and no history of trauma. He had a chondral lesion in the trochlear region of the femur and clinical tests compatible with pain in the anterior compartment of the knee. Conservative treatment failed to alleviate symptoms. Surgical treatment was indicated, but due to the size of the lesion, membrane-assisted autologous chondrocyte implantation was the technique of choice. Cartilage biopsies were collected from the intercondylar region of the distal femur. After isolation, chondrocytes were expanded ex vivo in a trained laboratory, for three weeks, and seeded onto a commercially available collagen membrane prior to implantation in the knee. Two days before surgery, a cell culture sample tested positive for Mycoplasma pneumoniae. The source of contamination was found to be autologous blood serum, extracted from the patient´s peripheral vein, and used to supplement the cell culture medium. After treating the patient with antibiotics, all procedures were repeated and the new final cell product, free from contaminants, was successfully implanted. We discuss the strategies available to deal with this situation, and describe the results of this particular case, which led to modifications in the autologous chondrocyte implant protocol.
Collapse
|
5
|
Ong KJ, Johnston J, Datar I, Sewalt V, Holmes D, Shatkin JA. Food safety considerations and research priorities for the cultured meat and seafood industry. Compr Rev Food Sci Food Saf 2021; 20:5421-5448. [PMID: 34633147 DOI: 10.1111/1541-4337.12853] [Citation(s) in RCA: 48] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Revised: 08/31/2021] [Accepted: 09/04/2021] [Indexed: 12/14/2022]
Abstract
Cell-cultured meat and seafood offer a sustainable opportunity to meet the world's increasing demand for protein in a climate-changed world. A responsible, data-driven approach to assess and demonstrate safety of cell-cultured meat and seafood can support consumer acceptance and help fully realize the potential of these products. As an initial step toward a thorough demonstration of safety, this review identifies hazards that could be introduced during manufacturing, evaluates applicability of existing safety assessment approaches, and highlights research priorities that could support safe commercialization. Input was gathered from members of the cultured meat and seafood industry, researchers, regulators, and food safety experts. A series of workshops were held with 87 industry representatives and researchers to create a modular manufacturing process diagram, which served as a framework to identify potential chemical and biological hazards along the steps of the manufacturing process that could affect the safety of a final food product. Interviews and feedback on draft documents validated the process diagram and supported hazard identification and evaluation of applicable safety methods. Most hazards are not expected to be novel; therefore, safety assessment methods from a range of fields, such as conventional and novel foods, foods produced from biotechnology, pharmaceuticals, and so forth, are likely to be applicable. However, additional assessment of novel inputs or products with significant differences from existing foods may be necessary. Further research on the safety of the inputs and associated residues, potential for contamination, and development of standardized safety assessment approaches (particularly animal-free methods) is recommended.
Collapse
Affiliation(s)
| | | | - Isha Datar
- New Harvest Inc., Cambridge, Massachusetts, USA
| | | | | | | |
Collapse
|
6
|
Mathews S, Rabani R, Rasti M, Viswanathan S. In-house abbreviated qualification of a real-time polymerase chain reaction method and strategies to amplify mycoplasma detection in human mesenchymal stromal cells. Cytotherapy 2021; 23:1036-1044. [PMID: 34446358 DOI: 10.1016/j.jcyt.2021.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Revised: 06/27/2021] [Accepted: 07/02/2021] [Indexed: 11/25/2022]
Abstract
BACKGROUND AIMS In this study, the authors performed an in-house abbreviated qualification of a commercially available real-time polymerase chain reaction (PCR) kit for limit of detection (LOD), matrix interference and ruggedness of mycoplasma detection in a human bone marrow-derived mesenchymal stromal cell (MSC(M)) investigational cell product (NCT02351011). The approach used was similar to an abbreviated qualification the authors previously conducted for endpoint PCR, which was accepted by Canadian regulators for final product release of the same MSC(M) investigational cell product for treatment of osteoarthritis patients (NCT02351011). With patient consent, biobanked MSCs(M) were re-analyzed by real-time PCR for mycoplasma detection to conduct in-house qualification of the kit. METHODS LOD was determined by spiking MSCs(M) with a series of 10-fold dilutions of two commercially available genomic DNA (gDNA) reference standards for Mycoplasma arginini (M. arginini) and Mycoplasma hominis (M. hominis). Matrix interference was tested by using 10-fold dilutions of MSC(M)s down to 4500 cells/mL. Polyadenylic acid (poly[A]) was used to improve DNA recovery in samples with 4500-45 000 MSCs(M)/mL. Real-time PCR tests performed on different days were compared to evaluate ruggedness. RESULTS Real-time PCR analysis showed a conservative LOD of 40 genome copies (GCs)/mL and 240 GCs/mL, which are equivalent to 10 colony-forming units (CFUs)/mL, for M. arginini and M. hominis, respectively. According to a less conservative manufacturer-based criterion for positivity, the kit detected 0.4 GC/mL (0.1 CFU/mL) and 24 GCs/mL (1 CFU/mL) M. arginini and M. hominis, respectively. Real-time PCR with different MSC(M) dilutions did not show matrix interference. However, DNA recovery was compromised at MSC(M) concentrations at or below 45 000 cells/mL. The addition of poly(A) as a DNA carrier improved DNA recovery and allowed an LOD, considered here to be equivalent to 10 CFUs/mL, to be achieved, which was not possible in diluted MSC(M) samples (≤45 000 cells/mL) in the absence of poly(A). Ruggedness was demonstrated with tests (n = 18) performed on different days, with an average overall inter-assay percent coefficient of variation of less than 4 for M. arginini (3.62 [400 GCs/mL], 3.61 [40 GCs/mL]) and less than 3 for M. hominis (2.83 [2400 GCs/mL], 1.95 [240 GCs/mL]). CONCLUSIONS A commercially available real-time PCR mycoplasma detection kit was qualified for evaluating mycoplasma contamination in investigational MSC(M) products and met the criteria used previously (and accepted by Canadian regulators) for in-house qualification of an endpoint PCR mycoplasma detection kit, and the addition of poly(A) addressed the poor recovery of mycoplasma gDNA in samples with low cell numbers.
Collapse
Affiliation(s)
- Smitha Mathews
- Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Canada
| | - Razieh Rabani
- Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Canada
| | - Mozhgan Rasti
- Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Canada
| | - Sowmya Viswanathan
- Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Canada; Krembil Research Institute, University Health Network, Toronto, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Canada; Division of Hematology, Department of Medicine, University of Toronto, Toronto, Canada.
| |
Collapse
|
7
|
A practical approach for gmp-compliant validation of real-time PCR method for mycoplasma detection in human mesenchymal stromal cells as advanced therapy medicinal product. Biologicals 2021; 73:31-40. [PMID: 34362616 DOI: 10.1016/j.biologicals.2021.07.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 07/26/2021] [Accepted: 07/30/2021] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Manufacturing of human Mesenchymal Stromal Cells as advanced therapy medicinal product (ATMP) for clinical use involves an ex vivo expansion, which leads to a risk of contamination by microbiological agents. Even if manufacturing under Good Manufacturing Practice (GMP) license minimizes this risk, contamination of cell cultures by mycoplasmas still represents a widespread problem. Furthermore, the absence of mycoplasma contamination represents one of ATMPs release criteria. Since July 2007, European Pharmacopoeia (EuPh) offers the possibility to replace official mycoplasma detection methods with Nucleic Acid Amplification techniques, after suitable validation. As an Italian authorized Cell Factory, we developed an in-house GMP-compliant validation of real-time PCR method for mycoplasma detection in human Mesenchymal Stromal Cells, according to EuPh sec. 2.6.7 and International Conference on Harmonization Q2. MATERIALS AND METHODS The study was performed in compliance with GMP international requirements with MycoSEQ™ Mycoplasma Detection Assay (Thermofisher) on QuantStudio5 real-Time PCR (Applied Biosystems). Assay validation was developed to evaluate sensitivity, interferences matrix-related, specificity and robustness. RESULTS MycoSEQ™ Mycoplasma Detection Assay has been successfully validated on human Mesenchymal Stromal Cells as results comply with validation protocol acceptance criteria. CONCLUSIONS MycoSEQ™ Mycoplasma Detection Assay is a fast, sensitive and specific PCR-based Nucleic Acid Test assay that can be used as an alternative to official mycoplasma test methods for lot release of human Mesenchymal Stromal Cells as advanced therapy medicinal product (ATMP). Moreover, our study underlines the presence of interference on real-time PCR reaction due to matrix composition, pointing out a practical approach for method validation (i.e interference removal).
Collapse
|
8
|
Gómez Rufo D, García Sánchez E, García Sánchez JE, García Moro M. [Clinical implications of the genus Mycoplasma]. REVISTA ESPANOLA DE QUIMIOTERAPIA 2021; 34:169-184. [PMID: 33735544 PMCID: PMC8179937 DOI: 10.37201/req/014.2021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Dentro del género Mycoplasma, las especies que tradicionalmente se han relacionado con cuadros infecciosos han sido principalmente M. pneumoniae, M. genitalium, M. hominis o U. urealyticum. Sin embargo, existen otras muchas que están implicadas y, que muchas veces, son desconocidas para los profesionales sanitarios. El objetivo de esta revisión es identificar todas las especies del género Mycoplasma que se han aislado en el hombre y determinar su participación en la patología infecciosa humana.
Collapse
Affiliation(s)
| | - E García Sánchez
- Enrique García Sánchez, Departamento de Ciencias Biomédicas. Facultad de Medicina. Universidad de Salamanca. Spain.
| | | | | |
Collapse
|
9
|
Pasqua S, Vitale G, Pasquariello A, Douradinha B, Tuzzolino F, Cardinale F, Cusimano C, Di Bartolo C, Conaldi PG, D'Apolito D. Use of 27G needles improves sensitivity and performance of ATCC anaerobe reference microorganism detection in BacT/Alert system. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT 2021; 20:542-550. [PMID: 33665224 PMCID: PMC7890369 DOI: 10.1016/j.omtm.2021.01.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Accepted: 01/18/2021] [Indexed: 11/26/2022]
Abstract
Effective detection of microbiological contaminations present in medicinal cellular products is a crucial step to ensure patients' safety. In recent decades, several rapid microbiological methods have been developed and validated, but variabilities linked to the use of different resources have led to discordant validation of methods and performance results. Considering this, while developing an in-house BacT/Alert-based method, we evaluated all of the materials used in its validation. Of particular importance, we noticed that the syringe gauge used to inject the samples into the bottles was crucial to obtain robust results. We chose to conduct a comparative test between the BacT/Alert system and the compendial method described in the European Pharmacopoeia, using five dilutions of nine reference microorganism strains and 21G or 27G needles. Our results confirmed that the BacT/Alert system is a valid and faster alternative method to assess sterility of clinical cell therapy products, and that the use of 27G needles increases its sensitivity to detect reference anaerobe microorganisms.
Collapse
Affiliation(s)
- Salvatore Pasqua
- Unità Prodotti Cellulari (GMP), Fondazione Ri.MED c/o IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90127 Palermo, Italy
| | - Giampiero Vitale
- Unità Prodotti Cellulari (GMP), Fondazione Ri.MED c/o IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90127 Palermo, Italy
| | - Anna Pasquariello
- Unità di Medicina di Laboratorio e Biotecnologie Avanzate, IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy
| | - Bruno Douradinha
- Unità di Medicina di Laboratorio e Biotecnologie Avanzate, IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy.,Unità Medicina Rigenerativa ed Immunologia, Fondazione Ri.MED c/o IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy
| | - Fabio Tuzzolino
- Ufficio Ricerca, IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy
| | - Francesca Cardinale
- Unità di Medicina di Laboratorio e Biotecnologie Avanzate, IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy
| | - Chiara Cusimano
- Unità di Medicina di Laboratorio e Biotecnologie Avanzate, IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy
| | - Chiara Di Bartolo
- Unità Prodotti Cellulari (GMP), Fondazione Ri.MED c/o IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90127 Palermo, Italy.,Unità di Medicina di Laboratorio e Biotecnologie Avanzate, IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy
| | - Pier Giulio Conaldi
- Unità di Medicina di Laboratorio e Biotecnologie Avanzate, IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy
| | - Danilo D'Apolito
- Unità Prodotti Cellulari (GMP), Fondazione Ri.MED c/o IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90127 Palermo, Italy.,Unità di Medicina di Laboratorio e Biotecnologie Avanzate, IRCCS-ISMETT, Via E. Tricomi 5, 90127 Palermo, Italy
| |
Collapse
|
10
|
Lam C, Meinert E, Yang A, Cui Z. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation. Cytotherapy 2021; 23:433-451. [PMID: 33674239 DOI: 10.1016/j.jcyt.2020.08.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 07/21/2020] [Accepted: 08/16/2020] [Indexed: 11/25/2022]
Abstract
BACKGROUND AIMS Decentralized, or distributed, manufacturing that takes place close to the point of care has been a manufacturing paradigm of heightened interest within the cell therapy domain because of the product's being living cell material as well as the need for a highly monitored and temperature-controlled supply chain that has the potential to benefit from close proximity between manufacturing and application. METHODS To compare the operational feasibility and cost implications of manufacturing autologous chimeric antigen receptor T (CAR T)-cell products between centralized and decentralized schemes, a discrete event simulation model was built using ExtendSIM 9 for simulating the patient-to-patient supply chain, from the collection of patient cells to the final administration of CAR T therapy in hospitals. Simulations were carried out for hypothetical systems in the UK using three demand levels-low (100 patients per annum), anticipated (200 patients per annum) and high (500 patients per annum)-to assess resource allocation, cost per treatment and system resilience to demand changes and to quantify the risks of mix-ups within the supply chain for the delivery of CAR T treatments. RESULTS The simulation results show that although centralized manufacturing offers better economies of scale, individual facilities in a decentralized system can spread facility costs across a greater number of treatments and better utilize resources at high demand levels (annual demand of 500 patients), allowing for an overall more comparable cost per treatment. In general, raw material and consumable costs have been shown to be one of the greatest cost drivers, and genetic modification-associated costs have been shown to account for over one third of raw material and consumable costs. Turnaround time per treatment for the decentralized scheme is shown to be consistently lower than its centralized counterpart, as there is no need for product freeze-thaw, packaging and transportation, although the time savings is shown to be insignificant in the UK case study because of its rather compact geographical setting with well-established transportation networks. In both schemes, sterility testing lies on the critical path for treatment delivery and is shown to be critical for treatment turnaround time reduction. CONCLUSIONS Considering both cost and treatment turnaround time, point-of-care manufacturing within the UK does not show great advantages over centralized manufacturing. However, further simulations using this model can be used to understand the feasibility of decentralized manufacturing in a larger geographical setting.
Collapse
Affiliation(s)
- Ching Lam
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK
| | - Edward Meinert
- Department of Paediatrics, University of Oxford, Oxford, UK
| | - Aidong Yang
- Department of Engineering Science, University of Oxford, Oxford, UK
| | - Zhanfeng Cui
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
| |
Collapse
|
11
|
Lopes BRP, Ribeiro AG, Silva TF, Barbosa LV, Jesus TI, Matsuda BK, Costa MF, Toledo KA. Diagnosis and treatment of HEp-2 cells contaminated with mycoplasma. BRAZ J BIOL 2021; 81:37-43. [PMID: 32321065 DOI: 10.1590/1519-6984.215721] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Accepted: 08/20/2019] [Indexed: 11/22/2022] Open
Abstract
Contamination of primary and cell cultures by mycoplasmas is one of the main economic and biological pitfalls in basic research, diagnosis and manufacture of biotechnological products. It is a common issue which may be difficult to conduct surveillance on. Mycoplasma presence may affect several physiological parameters of the cell, besides being considered an important source of inaccurate and/or non-reproducible scientific results. Each cell type presents characteristical symptoms, mainly morphological, that indicate a contamination by mycoplasma. HEp-2 cells originate from carcinoma of the larynx and are, therefore, part of the respiratory tract, which is one of mycoplasma habitats. Despite the importance these cells in several biological research (evaluation of cell proliferation and migration, apoptosis, antiviral and antitumor compounds), the alterations induced by mycoplasma contamination in HEp-2 cells have not yet been described. Here, we describe the progressive morphological alterations in culture of HEp-2 cells infected with mycoplasma, as well as the-diagnosis of the infection and its treatment. Mycoplasma contamination described within this work led to cytoplasm elongation, cell-to-cell spacing, thin plasma membrane projections, cytoplasmic vacuoles, fusion with neighboring cells, and, finally, cell death. Contamination was detected by fluorescence imaging (DAPI) and PCR reactions. The cultures were treated with BM-Cyclin antibiotic to eliminate contamination. The data presented here will be of relevance to researchers whose investigations involve cell culture, especially respiratory and HEp-2 cells.
Collapse
Affiliation(s)
- B R P Lopes
- Departamento de Ciências Biológicas, Faculdade de Ciências e Letras, Universidade Estadual Paulista - UNESP, Av. Dom Antônio, 2100, Parque Universitário, CEP 19806-900, Assis, SP, Brasil.,Instituto de Biociências, Letras e Ciências Exatas - IBILCE, Universidade Estadual Paulista - UNESP, R. Cristovão Colombo, 2265, Jardim Nazareth, CEP 15054-000, São José do Rio Preto, SP, Brasil
| | - A G Ribeiro
- Departamento de Ciências Biológicas, Faculdade de Ciências e Letras, Universidade Estadual Paulista - UNESP, Av. Dom Antônio, 2100, Parque Universitário, CEP 19806-900, Assis, SP, Brasil.,Instituto de Biociências, Letras e Ciências Exatas - IBILCE, Universidade Estadual Paulista - UNESP, R. Cristovão Colombo, 2265, Jardim Nazareth, CEP 15054-000, São José do Rio Preto, SP, Brasil
| | - T F Silva
- Departamento de Ciências Biológicas, Faculdade de Ciências e Letras, Universidade Estadual Paulista - UNESP, Av. Dom Antônio, 2100, Parque Universitário, CEP 19806-900, Assis, SP, Brasil
| | - L V Barbosa
- Departamento de Ciências Biológicas, Faculdade de Ciências e Letras, Universidade Estadual Paulista - UNESP, Av. Dom Antônio, 2100, Parque Universitário, CEP 19806-900, Assis, SP, Brasil
| | - T I Jesus
- Departamento de Ciências Biológicas, Faculdade de Ciências e Letras, Universidade Estadual Paulista - UNESP, Av. Dom Antônio, 2100, Parque Universitário, CEP 19806-900, Assis, SP, Brasil
| | - B K Matsuda
- Departamento de Ciências Biológicas, Faculdade de Ciências e Letras, Universidade Estadual Paulista - UNESP, Av. Dom Antônio, 2100, Parque Universitário, CEP 19806-900, Assis, SP, Brasil
| | - M F Costa
- Departamento de Ciências Biológicas, Faculdade de Ciências e Letras, Universidade Estadual Paulista - UNESP, Av. Dom Antônio, 2100, Parque Universitário, CEP 19806-900, Assis, SP, Brasil
| | - K A Toledo
- Departamento de Ciências Biológicas, Faculdade de Ciências e Letras, Universidade Estadual Paulista - UNESP, Av. Dom Antônio, 2100, Parque Universitário, CEP 19806-900, Assis, SP, Brasil.,Instituto de Biociências, Letras e Ciências Exatas - IBILCE, Universidade Estadual Paulista - UNESP, R. Cristovão Colombo, 2265, Jardim Nazareth, CEP 15054-000, São José do Rio Preto, SP, Brasil
| |
Collapse
|
12
|
Flow-Cytometric Method for Viability Analysis of Mycoplasma gallisepticum and Other Cell-Culture-Contaminant Mollicutes. Curr Microbiol 2020; 78:67-77. [PMID: 33159562 DOI: 10.1007/s00284-020-02255-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 10/14/2020] [Indexed: 10/23/2022]
Abstract
Mycoplasma is the smallest self-replicating bacteria, figuring as common contaminant of eukaryotic cell cultures. Production inputs and operator's manipulation seem to be the main sources of such contamination. Many analytical approaches have been applied for mycoplasma detection in cell cultures and also in biological products. However, unless they were validated, only indicator cell culture and bacteriological culture are considered as compendial methods for quality control of biological products. Nano-flow cytometry has been pointed out as an alternative technique for addressing prokaryotic and eukaryotic cell viability being a substantial tool for reference material production. In this study, a viability-flow-cytometry assay was standardized for M. gallisepticum and then applied to other cell-culture-contaminant mycoplasmas. For this, M. galliseticum's growth rate was observed and different treatments were evaluated to establish low viability cultures (cell death-induced control). Distinct viability markers and their ideal concentrations (titration) were appraised. Ethanol treatment showed to be the best death-inducing control. CFDA and TOPRO markers revealed to be the best choice for detecting live and dead mycoplasma frequencies, respectively. The standardized methodology was applied to Mycoplasma arginini, M. hyorhinis, M. orale, Spiroplasma citri and Acholeplasma laidlawii. Significant statistical difference was observed in the percentage of viable cells in comparison to ethanol treatment for A. laidlawii in CFDA and in both markers for M. gallisepticum, M. hyorhinis and S. citri. In summary, we standardized a flow cytometry assay for assessing M. gallisepticum - and potentially other species - viability and ultimately applied for reference material production improving the quality control of biological products.
Collapse
|
13
|
Nelissen I, Haase A, Anguissola S, Rocks L, Jacobs A, Willems H, Riebeling C, Luch A, Piret JP, Toussaint O, Trouiller B, Lacroix G, Gutleb AC, Contal S, Diabaté S, Weiss C, Lozano-Fernández T, González-Fernández Á, Dusinska M, Huk A, Stone V, Kanase N, Nocuń M, Stępnik M, Meschini S, Ammendolia MG, Lewinski N, Riediker M, Venturini M, Benetti F, Topinka J, Brzicova T, Milani S, Rädler J, Salvati A, Dawson KA. Improving Quality in Nanoparticle-Induced Cytotoxicity Testing by a Tiered Inter-Laboratory Comparison Study. NANOMATERIALS 2020; 10:nano10081430. [PMID: 32707981 PMCID: PMC7466672 DOI: 10.3390/nano10081430] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 07/13/2020] [Accepted: 07/17/2020] [Indexed: 12/28/2022]
Abstract
The quality and relevance of nanosafety studies constitute major challenges to ensure their key role as a supporting tool in sustainable innovation, and subsequent competitive economic advantage. However, the number of apparently contradictory and inconclusive research results has increased in the past few years, indicating the need to introduce harmonized protocols and good practices in the nanosafety research community. Therefore, we aimed to evaluate if best-practice training and inter-laboratory comparison (ILC) of performance of the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay for the cytotoxicity assessment of nanomaterials among 15 European laboratories can improve quality in nanosafety testing. We used two well-described model nanoparticles, 40-nm carboxylated polystyrene (PS-COOH) and 50-nm amino-modified polystyrene (PS-NH2). We followed a tiered approach using well-developed standard operating procedures (SOPs) and sharing the same cells, serum and nanoparticles. We started with determination of the cell growth rate (tier 1), followed by a method transfer phase, in which all laboratories performed the first ILC on the MTS assay (tier 2). Based on the outcome of tier 2 and a survey of laboratory practices, specific training was organized, and the MTS assay SOP was refined. This led to largely improved intra- and inter-laboratory reproducibility in tier 3. In addition, we confirmed that PS-COOH and PS-NH2 are suitable negative and positive control nanoparticles, respectively, to evaluate impact of nanomaterials on cell viability using the MTS assay. Overall, we have demonstrated that the tiered process followed here, with the use of SOPs and representative control nanomaterials, is necessary and makes it possible to achieve good inter-laboratory reproducibility, and therefore high-quality nanotoxicological data.
Collapse
Affiliation(s)
- Inge Nelissen
- Health Department, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400 Mol, Belgium; (A.J.); (H.W.)
- Correspondence: ; Tel.: +32-14-335107
| | - Andrea Haase
- Department of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany; (A.H.); (C.R.); (A.L.)
| | - Sergio Anguissola
- Centre for BioNano Interactions, University College Dublin (UCD), Belfield, Dublin 4, Ireland; (S.A.); (L.R.); (A.S.); (K.A.D.)
- Charles River Laboratories, Carrowntreila, Ballina, Co. Mayo, Ireland
| | - Louise Rocks
- Centre for BioNano Interactions, University College Dublin (UCD), Belfield, Dublin 4, Ireland; (S.A.); (L.R.); (A.S.); (K.A.D.)
- Science Foundation Ireland, Three Park Place, Hatch Street Upper, Dublin 2, Ireland
| | - An Jacobs
- Health Department, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400 Mol, Belgium; (A.J.); (H.W.)
| | - Hanny Willems
- Health Department, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400 Mol, Belgium; (A.J.); (H.W.)
| | - Christian Riebeling
- Department of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany; (A.H.); (C.R.); (A.L.)
| | - Andreas Luch
- Department of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany; (A.H.); (C.R.); (A.L.)
| | - Jean-Pascal Piret
- Research Unit in Cellular Biology (URBC), Namur Nanosafety Center (NNC), Namur Research Institute for Life Sciences (NARILIS), University of Namur (UNamur), rue de Bruxelles 61, 5000 Namur, Belgium;
| | - Olivier Toussaint
- Research Unit in Cellular Biology (URBC), Namur Nanosafety Center (NNC), Namur Research Institute for Life Sciences (NARILIS), University of Namur (UNamur), rue de Bruxelles 61, 5000 Namur, Belgium;
| | - Bénédicte Trouiller
- Experimental Toxicology Unit, Institut National de l’Environnement Industriel et des Risques (INERIS), Parc Alata, BP2, 60550 Verneuil-en-Halatte, France; (B.T.); (G.L.)
| | - Ghislaine Lacroix
- Experimental Toxicology Unit, Institut National de l’Environnement Industriel et des Risques (INERIS), Parc Alata, BP2, 60550 Verneuil-en-Halatte, France; (B.T.); (G.L.)
| | - Arno C. Gutleb
- Environmental Research and Innovation (ERIN) Department, Luxembourg Institute of Science and Technology (LIST), 41, rue du Brill, L-4422 Belvaux, Luxembourg; (A.C.G.); (S.C.)
| | - Servane Contal
- Environmental Research and Innovation (ERIN) Department, Luxembourg Institute of Science and Technology (LIST), 41, rue du Brill, L-4422 Belvaux, Luxembourg; (A.C.G.); (S.C.)
| | - Silvia Diabaté
- Institute of Toxicology and Genetics, Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany; (S.D.); (C.W.)
| | - Carsten Weiss
- Institute of Toxicology and Genetics, Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany; (S.D.); (C.W.)
| | - Tamara Lozano-Fernández
- Biomedical Research Center (CINBIO), University of Vigo, Campus Lagoas Marcosende, 36310 Vigo, Spain; (T.L.-F.); (Ã.G.-F.)
- Nanoimmunotech SL, Edificio CITEXVI Fonte das Abelleiras s/n, Campus Universitario de Vigo, 36310 Vigo, Pontevedra, Spain
| | - África González-Fernández
- Biomedical Research Center (CINBIO), University of Vigo, Campus Lagoas Marcosende, 36310 Vigo, Spain; (T.L.-F.); (Ã.G.-F.)
- Instituto de Investigación Sanitaria Galicia Sur (IISGS), Hospital Álvaro Cunqueiro, Estrada Clara Campoamor 341, Babio – Beade, 36312 Vigo, Spain
| | - Maria Dusinska
- Health Effects Laboratory, Department of Environmental Chemistry, Norwegian Institute for Air Research (NILU), Instituttveien 18, 2007 Kjeller, Norway; (M.D.); (A.H.)
| | - Anna Huk
- Health Effects Laboratory, Department of Environmental Chemistry, Norwegian Institute for Air Research (NILU), Instituttveien 18, 2007 Kjeller, Norway; (M.D.); (A.H.)
- Gentian Diagnostics AS, Bjørnåsveien 5, 1596 Moss, Norway
| | - Vicki Stone
- School of Life Sciences, Heriot-Watt University (HWU), Riccarton Campus, Edinburgh EH14 4AS, UK; (V.S.); (N.K.)
| | - Nilesh Kanase
- School of Life Sciences, Heriot-Watt University (HWU), Riccarton Campus, Edinburgh EH14 4AS, UK; (V.S.); (N.K.)
| | - Marek Nocuń
- Department of Toxicology and Carcinogenesis, Nofer Institute of Occupational Medicine (NIOM), 91-348 Łódź, Poland; (M.N.); (M.S.)
- SEQme s.r.o., Dlouha 176, 26301 Dobris, Czech Republic
| | - Maciej Stępnik
- Department of Toxicology and Carcinogenesis, Nofer Institute of Occupational Medicine (NIOM), 91-348 Łódź, Poland; (M.N.); (M.S.)
| | - Stefania Meschini
- National Center for Drug Research and Evaluation and National Center of Innovative Technologies for Public Health, Istituto Superiore di Sanità (ISS), Viale Regina Elena, 299 Rome, Italy; (S.M.); (M.G.A.)
| | - Maria Grazia Ammendolia
- National Center for Drug Research and Evaluation and National Center of Innovative Technologies for Public Health, Istituto Superiore di Sanità (ISS), Viale Regina Elena, 299 Rome, Italy; (S.M.); (M.G.A.)
| | - Nastassja Lewinski
- Institute for Work and Health (IST), University of Lausanne and University of Geneva, Route de la Corniche 2, 1066 Epalinges-Lausanne, Switzerland; (N.L.); (M.R.)
- Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23284, USA
| | - Michael Riediker
- Institute for Work and Health (IST), University of Lausanne and University of Geneva, Route de la Corniche 2, 1066 Epalinges-Lausanne, Switzerland; (N.L.); (M.R.)
- Swiss Centre for Occupational and Environmental Health (SCOEH), Binzhofstrasse 87, 8404 Winterthur, Switzerland
- School of Materials Science & Engineering, Nanyang Technological University, Block N4.1, Nanyang Avenue, Singapore 639798, Singapore
| | - Marco Venturini
- ECAMRICERT SRL, European Center for the Sustainable Impact of Nanotechnology (ECSIN), Corso Stati Uniti 4, 35127 Padova, Italy; (M.V.); (F.B.)
| | - Federico Benetti
- ECAMRICERT SRL, European Center for the Sustainable Impact of Nanotechnology (ECSIN), Corso Stati Uniti 4, 35127 Padova, Italy; (M.V.); (F.B.)
| | - Jan Topinka
- Institute of Experimental Medicine (IEM), Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic; (J.T.); (T.B.)
| | - Tana Brzicova
- Institute of Experimental Medicine (IEM), Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic; (J.T.); (T.B.)
- Faculty of Safety Engineering, VSB-Technical University of Ostrava, Lumirova 13, 70030 Ostrava-Vyskovice, Czech Republic
| | - Silvia Milani
- Faculty of Physics and Center for NanoScience, Ludwig-Maximilians-Universität, Geshwister-Scholl-Platz 1, 80539 Munich, Germany; (S.M.); (J.R.)
| | - Joachim Rädler
- Faculty of Physics and Center for NanoScience, Ludwig-Maximilians-Universität, Geshwister-Scholl-Platz 1, 80539 Munich, Germany; (S.M.); (J.R.)
| | - Anna Salvati
- Centre for BioNano Interactions, University College Dublin (UCD), Belfield, Dublin 4, Ireland; (S.A.); (L.R.); (A.S.); (K.A.D.)
- Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, 9713AV Groningen, The Netherlands
| | - Kenneth A. Dawson
- Centre for BioNano Interactions, University College Dublin (UCD), Belfield, Dublin 4, Ireland; (S.A.); (L.R.); (A.S.); (K.A.D.)
| |
Collapse
|
14
|
Gebo JET, Lau AF. Sterility Testing for Cellular Therapies: What Is the Role of the Clinical Microbiology Laboratory? J Clin Microbiol 2020; 58:e01492-19. [PMID: 32321785 PMCID: PMC7315024 DOI: 10.1128/jcm.01492-19] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Sterility testing of cellular therapy products along with the associated environmental monitoring requirements for aseptic facilities, including compounding pharmacies, continues to impact clinical microbiology laboratories, as evidenced by the numerous discussions recurring on American Society for Microbiology Division C and ClinMicroNet listservs. This minireview provides an overview of this complex field of current good manufacturing practices (cGMP) based on biopharmaceutical industry standards and summarizes the compendial and alternative rapid microbial test methods available for product sterility and Mycoplasma testing. In addition, this minireview highlights major overarching regulatory requirements governing any laboratory performing product testing as regulated by the United States Food and Drug Administration (FDA). These requirements are different from the more familiar clinical requirements of the Clinical Laboratory Improvement Act of 1988 (CLIA '88), the College of American Pathologists (CAP), and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO), all of which have no jurisdiction in this area. As the cellular therapy field continues to advance and an increasing number of medical centers participate in clinical trials of these novel therapies, it is critical that laboratories have a sound understanding of the major regulations and cGMP practices governing microbiological testing in the biopharmaceutical industry.
Collapse
Affiliation(s)
- James E T Gebo
- Sterility Testing Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
| | - Anna F Lau
- Sterility Testing Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
15
|
Desbrousses C, Archer F, Colin A, Bobet-Erny A, Champavère A, Gros E, Beurdeley P, Cruveiller S, Tardy F, Eloit M. High-Throughput Sequencing (HTS) of newly synthetized RNAs enables one shot detection and identification of live mycoplasmas and differentiation from inert nucleic acids. Biologicals 2020; 65:18-24. [PMID: 32222272 DOI: 10.1016/j.biologicals.2020.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 02/19/2020] [Accepted: 03/11/2020] [Indexed: 11/26/2022] Open
Abstract
Mycoplasma contamination threatens both the safety of biologics produced in cell substrates as well as the quality of scientific results based on cell-culture observations. Methods currently used to detect contamination of cells include culture, enzymatic activity, immunofluorescence and PCR but suffer from some limitations. High throughput sequencing (HTS) can be used to identify microbes like mycoplasmas in biologics since it enables an unbiased approach to detection without the need to design specific primers to pre-amplify target sequences but it does not enable the confirmation of microbial infection since this could reflect carryover of inert sequences. In order to unambiguously differentiate the presence of live or dead mycoplasmas in biological products, the present method was developed based on metabolic RNA labelling of newly synthetized mycoplasmal RNAs. HTS of labelled RNA detected A549 cell infection with Acholeplasma laidlawii in a manner similar to both PCR and culture and demonstrated that this technique can unambiguously identify bacterial species and differentiates infected cells from cells exposed to a high inoculum of heat-inactivated mycoplasmas. This method therefore combines the advantage of culture (that detects only live microorganisms) with those of molecular tests (rapidity) together with a very broad range of bacterial detection and identification.
Collapse
Affiliation(s)
| | - Fabienne Archer
- University of Lyon, Université Claude Bernard Lyon1, INRAE, EPHE, IVPC, Viral Infections and Comparative Pathology, UMR754, F69007, Lyon, France
| | - Adélie Colin
- Université de Lyon, Anses Laboratoire de Lyon, VetAgro Sup, UMR Mycoplasmoses des Ruminants, F69364, Lyon, France
| | - Alexandra Bobet-Erny
- University of Lyon, Université Claude Bernard Lyon1, INRAE, EPHE, IVPC, Viral Infections and Comparative Pathology, UMR754, F69007, Lyon, France
| | - Angélique Champavère
- University of Lyon, Université Claude Bernard Lyon1, INRAE, EPHE, IVPC, Viral Infections and Comparative Pathology, UMR754, F69007, Lyon, France
| | | | | | | | - Florence Tardy
- Université de Lyon, Anses Laboratoire de Lyon, VetAgro Sup, UMR Mycoplasmoses des Ruminants, F69364, Lyon, France
| | - Marc Eloit
- PathoQuest, Paris, France; Ecole Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, 94704 Cedex, France; Pathogen Discovery Laboratory, Institut Pasteur, Paris, France.
| |
Collapse
|
16
|
D'Apolito D, D'Aiello L, Pasqua S, Pecoraro L, Barbera F, Douradinha B, Di Martino G, Di Bartolo C, Conaldi PG. Strategy and validation of a consistent and reproducible nucleic acid technique for mycoplasma detection in advanced therapy medicinal products. Biologicals 2020; 64:49-57. [DOI: 10.1016/j.biologicals.2020.01.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Revised: 12/23/2019] [Accepted: 01/01/2020] [Indexed: 11/25/2022] Open
|
17
|
Hirsch C, Schildknecht S. In Vitro Research Reproducibility: Keeping Up High Standards. Front Pharmacol 2019; 10:1484. [PMID: 31920667 PMCID: PMC6916005 DOI: 10.3389/fphar.2019.01484] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Accepted: 11/15/2019] [Indexed: 12/23/2022] Open
Abstract
Concern regarding the reproducibility of observations in life science research has emerged in recent years, particularly in view of unfavorable experiences with preclinical in vivo research. The use of cell-based systems has increasingly replaced in vivo research and the application of in vitro models enjoys an ever-growing popularity. To avoid repeating past mistakes, high standards of reproducibility and reliability must be established and maintained in the field of in vitro biomedical research. Detailed guidance documenting the appropriate handling of cells has been authored, but was received with quite disparate perception by different branches in biomedical research. In that regard, we intend to raise awareness of the reproducibility issue among scientists in all branches of contemporary life science research and their individual responsibility in this matter. We have herein compiled a selection of the most susceptible steps of everyday in vitro cell culture routines that have the potential to influence cell quality and recommend practices to minimize the likelihood of poor cell quality impairing reproducibility with modest investment of time and resources.
Collapse
Affiliation(s)
- Cordula Hirsch
- Particles-Biology Interactions Laboratory, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen, Switzerland
| | - Stefan Schildknecht
- In vitro Toxicology and Biomedicine, Department of Biology, University of Konstanz, Konstanz, Germany
| |
Collapse
|
18
|
Standardization of Nucleic Acid Tests: the Approach of the World Health Organization. J Clin Microbiol 2019; 57:JCM.01056-18. [PMID: 30257900 DOI: 10.1128/jcm.01056-18] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The first World Health Organization (WHO) international standards (ISs) for nucleic acid amplification techniques were established two decades ago, with the initial focus on blood screening for three major viral targets, i.e., hepatitis C virus, hepatitis B virus, and human immunodeficiency virus 1. These reference materials have subsequently found utility in the diagnosis and monitoring of a wide range of infectious diseases in clinical microbiology laboratories worldwide. WHO collaborating centers develop ISs and coordinate international studies for their evaluation. The WHO Expert Committee on Biological Standardization is responsible for the endorsement of new standardization projects and the establishment of new and replacement ISs. Potencies of ISs are defined in international units (IU); the reporting in IU for assays calibrated with an IS (or secondary standards traceable to the IS) facilitates comparability of results for different assays and determination of assay parameters such as analytical sensitivities.
Collapse
|
19
|
Lai Y, Xu X, Yan R, Hua Z. Evaluation of mycoplasma removal reagents using qPCR-based quantification. Anal Biochem 2019; 564-565:88-95. [PMID: 30336125 DOI: 10.1016/j.ab.2018.10.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 10/09/2018] [Accepted: 10/10/2018] [Indexed: 11/30/2022]
Abstract
In this study, we evaluated the efficacy of various mycoplasma removal reagents using nuclear staining, DNA gel electrophoresis, and qPCR-based quantification. Our results showed Plasmocure and Plasmocin are two effective anti-mycoplasma reagents whose effects can be observed within a week. However, prolonged treatment with Plasmocin led to development of resistance. Withdrawal of anti-mycoplasma reagents led to reoccurrence of mycoplasma contamination, but addition of prevention reagent, such as Primocin, prevented recontamination. Therefore, sequential treatment by Plasmocure and Primocin is the best course of action against mycoplasma contamination. Lastly, we developed methods based on qPCR to estimate the average number of mycoplasma associated with a single contaminated cell. We have shown, for the first time, that untreated contaminated BEAS-2B cells have approximately 300-400 mycoplasma contaminants per cell in the cytoplasm or attached to the cell membrane. Furthermore, withdrawal of anti-mycoplasma reagents led to reoccurrence of mycoplasma contamination within two days, and therefore continued use of prevention reagent is imperative.
Collapse
Affiliation(s)
- Yueyang Lai
- School of Life Sciences and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
| | - Xuebo Xu
- School of Life Sciences and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
| | - Ruiying Yan
- School of Life Sciences and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
| | - Zichun Hua
- School of Life Sciences and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China; Changzhou High-Tech Research Institute of Nanjing University and Jiangsu Target Pharma Laboratories Inc., Changzhou, China; Shenzhen Research Institute of Nanjing University, Shenzhen, China.
| |
Collapse
|
20
|
Angart P, Kohnhorst C, Chiang MJ, Arden NS. Considerations for risk and control of mycoplasma in bioprocessing. Curr Opin Chem Eng 2018. [DOI: 10.1016/j.coche.2018.09.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
21
|
Abachin E, Marius M, Falque S, Arnaud J, Detrez V, Imbert S, Mallet L, Bonnevay T. Validation of a PCR coupled to a microarray method for detection of mycoplasma in vaccines. Biologicals 2017; 50:55-62. [DOI: 10.1016/j.biologicals.2017.09.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 08/07/2017] [Accepted: 09/02/2017] [Indexed: 11/26/2022] Open
|
22
|
Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev 2017; 30:747-809. [PMID: 28539503 PMCID: PMC5475226 DOI: 10.1128/cmr.00114-16] [Citation(s) in RCA: 367] [Impact Index Per Article: 52.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Mycoplasma pneumoniae is an important cause of respiratory tract infections in children as well as adults that can range in severity from mild to life-threatening. Over the past several years there has been much new information published concerning infections caused by this organism. New molecular-based tests for M. pneumoniae detection are now commercially available in the United States, and advances in molecular typing systems have enhanced understanding of the epidemiology of infections. More strains have had their entire genome sequences published, providing additional insights into pathogenic mechanisms. Clinically significant acquired macrolide resistance has emerged worldwide and is now complicating treatment. In vitro susceptibility testing methods have been standardized, and several new drugs that may be effective against this organism are undergoing development. This review focuses on the many new developments that have occurred over the past several years that enhance our understanding of this microbe, which is among the smallest bacterial pathogens but one of great clinical importance.
Collapse
Affiliation(s)
- Ken B Waites
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Li Xiao
- Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Yang Liu
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China, and Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China
| | | | - T Prescott Atkinson
- Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA
| |
Collapse
|
23
|
Corral-Vázquez C, Aguilar-Quesada R, Catalina P, Lucena-Aguilar G, Ligero G, Miranda B, Carrillo-Ávila JA. Cell lines authentication and mycoplasma detection as minimun quality control of cell lines in biobanking. Cell Tissue Bank 2017; 18:271-280. [PMID: 28255773 PMCID: PMC5429902 DOI: 10.1007/s10561-017-9617-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Accepted: 02/23/2017] [Indexed: 11/24/2022]
Abstract
Establishment of continuous cell lines from human normal and tumor tissues is an extended and useful methodology for molecular characterization of cancer pathophysiology and drug development in research laboratories. The exchange of these cell lines between different labs is a common practice that can compromise assays reliability due to contamination with microorganism such as mycoplasma or cells from different flasks that compromise experiment reproducibility and reliability. Great proportions of cell lines are contaminated with mycoplasma and/or are replaced by cells derived for a different origin during processing or distribution process. The scientific community has underestimated this problem and thousand of research experiment has been done with cell lines that are incorrectly identified and wrong scientific conclusions have been published. Regular contamination and authentication tests are necessary in order to avoid negative consequences of widespread misidentified and contaminated cell lines. Cell banks generate, store and distribute cell lines for research, being mandatory a consistent and continuous quality program. Methods implementation for guaranteeing both, the absence of mycoplasma and authentication in the supplied cell lines, has been performed in the Andalusian Health System Biobank. Specifically, precise results were obtained using real time PCR detection for mycoplasma and 10 STRs identification by capillary electrophoresis for cell line authentication. Advantages and disadvantages of these protocols are discussed.
Collapse
Affiliation(s)
- C Corral-Vázquez
- Andalusian Public Health System Biobank, Avenida Del Conocimiento S/N, 18016, Granada, Spain
| | - R Aguilar-Quesada
- Andalusian Public Health System Biobank, Avenida Del Conocimiento S/N, 18016, Granada, Spain
| | - P Catalina
- Andalusian Public Health System Biobank, Avenida Del Conocimiento S/N, 18016, Granada, Spain
| | - G Lucena-Aguilar
- Andalusian Public Health System Biobank, Avenida Del Conocimiento S/N, 18016, Granada, Spain
| | - G Ligero
- Andalusian Public Health System Biobank, Avenida Del Conocimiento S/N, 18016, Granada, Spain
| | - B Miranda
- Andalusian Public Health System Biobank, Avenida Del Conocimiento S/N, 18016, Granada, Spain
| | - J A Carrillo-Ávila
- Andalusian Public Health System Biobank, Avenida Del Conocimiento S/N, 18016, Granada, Spain.
| |
Collapse
|
24
|
Pla L, Xifré-Pérez E, Ribes À, Aznar E, Marcos MD, Marsal LF, Martínez-Máñez R, Sancenón F. A Mycoplasma
Genomic DNA Probe using Gated Nanoporous Anodic Alumina. Chempluschem 2017; 82:337-341. [DOI: 10.1002/cplu.201600651] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2016] [Indexed: 02/05/2023]
Affiliation(s)
- Luís Pla
- Departamento de Química; Universidad Politécnica de Valencia; Camino de Vera s/n 46022 Valencia Spain
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular; y Desarrollo Tecnológico (IDM); Universitat Politécnica de Valencia; Universitat de Valencia; Camino de Vera, s/n 46022 Valencia Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
| | - Elisabet Xifré-Pérez
- Departamento de Ingeniería Electrónica, Eléctrica y Automática; Universidad Rovira i Virgili; Avda. Paissos Catalans 26 43007 Tarragona Spain
| | - Àngela Ribes
- Departamento de Química; Universidad Politécnica de Valencia; Camino de Vera s/n 46022 Valencia Spain
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular; y Desarrollo Tecnológico (IDM); Universitat Politécnica de Valencia; Universitat de Valencia; Camino de Vera, s/n 46022 Valencia Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
| | - Elena Aznar
- Departamento de Química; Universidad Politécnica de Valencia; Camino de Vera s/n 46022 Valencia Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
| | - M. Dolores Marcos
- Departamento de Química; Universidad Politécnica de Valencia; Camino de Vera s/n 46022 Valencia Spain
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular; y Desarrollo Tecnológico (IDM); Universitat Politécnica de Valencia; Universitat de Valencia; Camino de Vera, s/n 46022 Valencia Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
| | - Lluís F. Marsal
- Departamento de Ingeniería Electrónica, Eléctrica y Automática; Universidad Rovira i Virgili; Avda. Paissos Catalans 26 43007 Tarragona Spain
| | - Ramón Martínez-Máñez
- Departamento de Química; Universidad Politécnica de Valencia; Camino de Vera s/n 46022 Valencia Spain
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular; y Desarrollo Tecnológico (IDM); Universitat Politécnica de Valencia; Universitat de Valencia; Camino de Vera, s/n 46022 Valencia Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
| | - Félix Sancenón
- Departamento de Química; Universidad Politécnica de Valencia; Camino de Vera s/n 46022 Valencia Spain
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular; y Desarrollo Tecnológico (IDM); Universitat Politécnica de Valencia; Universitat de Valencia; Camino de Vera, s/n 46022 Valencia Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
| |
Collapse
|
25
|
Loens K, Ieven M. Mycoplasma pneumoniae: Current Knowledge on Nucleic Acid Amplification Techniques and Serological Diagnostics. Front Microbiol 2016; 7:448. [PMID: 27064893 PMCID: PMC4814781 DOI: 10.3389/fmicb.2016.00448] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Accepted: 03/18/2016] [Indexed: 12/12/2022] Open
Abstract
Mycoplasma pneumoniae (M. pneumoniae) belongs to the class Mollicutes and has been recognized as a common cause of respiratory tract infections (RTIs), including community-acquired pneumonia (CAP), that occur worldwide and in all age groups. In addition, M. pneumoniae can simultaneously or sequentially lead to damage in the nervous system and has been associated with a wide variety of other acute and chronic diseases. During the past 10 years, the proportion of LRTI in children and adults, associated with M. pneumoniae infection has ranged from 0 to more than 50%. This variation is due to the age and the geographic location of the population examined but also due to the diagnostic methods used. The true role of M. pneumoniae in RTIs remains a challenge given the many limitations and lack of standardization of the applied diagnostic tool in most cases, with resultant wide variations in data from different studies. Correct and rapid diagnosis and/or management of M. pneumoniae infections is, however, critical to initiate appropriate antibiotic treatment and is nowadays usually done by PCR and/or serology. Several recent reviews, have summarized current methods for the detection and identification of M. pneumoniae. This review will therefore provide a look at the general principles, advantages, diagnostic value, and limitations of the most currently used detection techniques for the etiological diagnosis of a M. pneumoniae infection as they evolve from research to daily practice.
Collapse
Affiliation(s)
- Katherine Loens
- Department of Microbiology, National Reference Centre for Respiratory Pathogens, University Hospital Antwerp Antwerp, Belgium
| | - Margareta Ieven
- Department of Microbiology, National Reference Centre for Respiratory Pathogens, University Hospital Antwerp Antwerp, Belgium
| |
Collapse
|